Immunotech Laboratories Appoints New Chief Financial Advisor to
Strengthen Company's Growth and International Expansion Plan
PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ --
Immunotech Laboratories, Inc. (PINKSHEETS : IMMB )
Immunotech Laboratories, Inc., today announced the appointment
of Mr. Valentin Dimitrov to the
company Board of Directors as Chief Financial Advisor effective
immediately.
Mr. Dimitrov (48) has an impressive professional
history in the International Pharmaceutical World along with an
impressive background in the formation and management of
International Corporations, including the founding member and
supervisory Board Chairman of the International Orthodox Bank –
(present "Investbank" JSC).
Immunotech Director Bo Linton,
further commented Mr. Dimitrov has an extensive knowledge of the
Immunotech "IPF" patented technology and has worked alongside the
company for several years, assisting with International awareness
and potential Clinical Trial progression for the company's
Immunotherapy Treatments.
Immunotech President Harry
Zhabilov commented, "We are very pleased to announce the
appointment of Valentin to the Board of Directors and feel he will
be a valuable member of our team, and significantly help accelerate
the progression of the company towards FDA approval for the 'IPF'
technology."
The appointment of Mr. Dimitrov to Immunotech's Board of
Directors helps with the potential goal of upgrading the company to
the NASDAQ exchange, where a minimum of 5 Board Members are
required.
About
Valentin Lordanov Dimitrov
|
|
EDUCATION:
|
Kliment
Ohridski University
|
Master's
degree - Social Pedagogics
|
|
|
Kiev State
University, Ukraine
|
Bachelor
of International Diplomatic Relations
|
|
|
SPECIALIZATIONS:
|
1995:
|
University
of National and World Economy – Sofia - Finances
|
|
|
1999:
|
Chemical-technological University - Sofia -
Organic chemistry
|
|
|
LANGUAGES:
|
English -
Fluent , Russian - fluent , German – spoken
|
|
PROFESSIONAL BACKGROUND:
|
2007-Current:
|
"Vital-Fe"
LTD – Distribution of bio-technology and pharmaceutical products –
Director
|
|
|
2003-Present
|
"Bulgarian
Association of Chemical and Fertilizer Industry" –
Chairman
|
|
|
2002-2003
|
"Chimco
Vienna" GmbH – Distributor of chemical and pharmaceutical products
– Director
|
|
|
1999-2002
|
"CHIMCO"
JSC, Vratza - Chemical production plant - Chairman of the Board of
Directors
|
|
|
1992-1998
|
"Prima
Gas" JSC – supply of natural gas – Director
|
|
|
1995-1996
|
"International Orthodox Bank" – (present "Investbank"
JSC), Founder and member of the Supervisory Board
|
|
|
1994-1995
|
"Private
Agricultural and Investment Bank" – Member of the Supervisory
Board
|
|
|
1990-1991
|
"Pharmachem" JSC – pharmaceutical and chemical
industry – Director of Department
|
Safe Harbor Statement: This news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the
obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all, and the
successful outcome of such studies or tests. Therefore, there can
be no assurance that the forward-looking statements included in
this release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, Immunotech Laboratories or any other person that the
objectives and plans of Immunotech Laboratories will be achieved
should not regard the forward-looking statements as a
representation.
Company Contact:
ir@immunotechlab.com
Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup
CSNNewswire – Be Seen
www.csnnewswire.com
SOURCE Immunotech Laboratories, Inc.